About UDX
UDX is a company based in Sevilla (Spain) founded in 2012. UDX has raised $105.01 million across 7 funding rounds from investors including Olympus, Quest Diagnostics and European Investment Bank. UDX offers products and services including Signal C® and Cancer Platform. UDX operates in a competitive market with competitors including Delfi Diagnostics, Earli, Mirxes, Foresight Diagnostics and Haystack Oncology, among others.
- Headquarter Sevilla, Spain
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$105.01 M (USD)
in 7 rounds
-
Latest Funding Round
$35.01 M (USD), Series C
Jan 22, 2026
-
Investors
Olympus
& 5 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of UDX
UDX offers a comprehensive portfolio of products and services, including Signal C® and Cancer Platform.
Blood test for early detection of colorectal cancer.
Minimally-invasive blood-based solutions for early cancer identification.
People of UDX
Unlock access to complete
Unlock access to complete
Funding Insights of UDX
UDX has successfully raised a total of $105.01M across 7 strategic funding rounds. The most recent funding activity was a Series C round of $35.01 million completed in January 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in UDX
UDX has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Olympus, Quest Diagnostics and European Investment Bank.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Finance and advisory services for infrastructure projects are provided.
|
Locked | Locked | Locked | |
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for UDX
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by UDX
Investment portfolio details for UDX
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - UDX
Detailed financials for UDX
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Udx Comparisons
Peer comparison for UDX
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of UDX
UDX operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Delfi Diagnostics, Earli, Mirxes, Foresight Diagnostics and Haystack Oncology, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of DNA sequencing for cancer detection
|
|
| Locked | Locked | Locked |
Early cancer detection tests are developed using synthetic biomarkers.
|
|
| Locked | Locked | Locked |
miRNA-based tests for cancer detection are developed.
|
|
| Locked | Locked | Locked |
Minimally invasive liquid biopsy tests for cancer detection are developed.
|
|
| Locked | Locked | Locked |
Personalized cancer diagnostic tests are provided for minimal residual disease.
|
Detailed competitors of UDX
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Udx
Complete news archive for UDX
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about UDX
UDX was founded in 2012 and raised its 1st funding round 1 year after it was founded.
UDX is headquartered in Sevilla, Spain. It is registered at Sevilla, Andalucia, Spain.
UDX is a funded company, having raised a total of $105.01M across 7 funding rounds to date.
Founded in 2012 in Seville, Spain, the company operates in the biotechnology sector, focusing on non-invasive diagnostics. Blood samples from patients are analyzed using metabolomics to identify early indicators of cancer. Screening tests have been developed for colorectal, lung, and breast cancers, enabling detection through routine blood draws without invasive procedures. Operations center on advancing these diagnostic tools for clinical use.
UDX's top competitors include Delfi Diagnostics, Earli and Mirxes.
UDX offers Signal C® and Cancer Platform.
UDX has 6 investors. Key investors include Olympus, Quest Diagnostics, European Investment Bank, European Union, and EIC Fund.